Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares

Liquidia Corporation (NASDAQ:LQDAGet Free Report) CEO Roger Jeffs sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $40.10, for a total value of $1,002,500.00. Following the sale, the chief executive officer owned 1,398,095 shares in the company, valued at approximately $56,063,609.50. The trade was a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

  • On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total value of $1,052,250.00.
  • On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total value of $764,863.40.
  • On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total value of $1,003,500.00.
  • On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total value of $132,000.00.
  • On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total value of $1,256,387.28.
  • On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $859,891.96.
  • On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total value of $1,003,000.00.

Liquidia Stock Up 0.3%

NASDAQ:LQDA traded up $0.14 on Thursday, hitting $42.28. The stock had a trading volume of 1,196,501 shares, compared to its average volume of 1,625,170. The business’s fifty day moving average is $36.79 and its 200 day moving average is $34.57. The company has a market cap of $3.76 billion, a PE ratio of -50.94 and a beta of 0.41. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $46.67.

Liquidia (NASDAQ:LQDAGet Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The business had revenue of $92.02 million for the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The company’s revenue was up 3072.4% on a year-over-year basis. On average, equities research analysts expect that Liquidia Corporation will post 1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on LQDA shares. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Needham & Company LLC increased their price target on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, HC Wainwright increased their price objective on Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $43.44.

Read Our Latest Report on LQDA

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently modified their holdings of the stock. Covestor Ltd increased its position in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Liquidia by 7.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after acquiring an additional 422 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Liquidia during the fourth quarter valued at approximately $25,000. ProShare Advisors LLC increased its position in shares of Liquidia by 7.1% during the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after acquiring an additional 775 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Liquidia by 1.4% during the third quarter. Alliancebernstein L.P. now owns 67,050 shares of the company’s stock valued at $1,525,000 after acquiring an additional 900 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

Further Reading

Insider Buying and Selling by Quarter for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.